

# ISRAEL SIDE EVENT

## JPM WEEK 2026



January 12  
2026



# THE ISRAEL EXPORT INSTITUTE

**The Israel Export Institute (IEI)**, backed by member companies, private sector partners, and the Government of Israel, drives global business opportunities for Israeli exporters. By offering a broad range of export-oriented services for Israeli firms and complementary support for international organizations, the IEI fosters successful joint ventures, strategic alliances, and trade partnerships worldwide.

The **Health & Life Science Sector** is the leading hub for connecting Israel's 1,600+ life science companies with global partners to deliver cutting-edge solutions that address today's most pressing healthcare challenges.



## Innovation at Scale

By 2025, Israel boasts 1,800+ active life science companies, growing steadily from just 200 in the 1990s

**40%**

already generating revenue

**40+**

new startups per year

**For more information**, please visit the Israel Export Institute's website:

<https://export.gov.il/en/>

Or email Director of Health & Life Science, Karin Mor:

[karinkm@export.gov.il](mailto:karinkm@export.gov.il)



# THE FOREIGN TRADE ADMINISTRATION

**The Foreign Trade Administration** at the Ministry of Economy and Industry is responsible for managing and directing the international trade policy of the State of Israel.

The Administration's main activities include promoting trade and exports, initiating and maintaining trade agreements, attracting and facilitating foreign investments, and creating strategic cooperation with foreign companies.

Together with the Administration's team in Israel, we operate a network of 55 offices, including 41 Economic and Commercial Missions worldwide, which serve as the operational arm of the Ministry in the global markets.

Israel's Economic and Trade Missions are at the forefront of the Israeli government's efforts to boost our industries in foreign markets. Our network of highly experienced economic representatives provides a wide range of services to Israeli companies and to the international business community.

# Participating Companies

## Company

## Category

**AccuLine**

Artificial Intelligence  
Decision Support Systems  
Point of Care Diagnostics

**ActualSignal**

Mobile Healthcare  
Precision / Personalized Medicine  
Remote Monitoring

**AION Labs**

Drug discovery  
Drug development

**Alma Therapeutics**

Drug delivery

**Appscent Medical**

Assistive Technologies  
Proactive wellness / Patient Engagement  
Remote Monitoring

**Canopy Immuno-  
Therapeutics**

Precision / Personalized Medicine

**CoPilotMD**

Artificial Intelligence  
Decision Support Systems  
Hospital Operational Efficiency

**Emet Surgical**

Artificial Intelligence  
Decision Support Systems  
Minimally Invasive System

# Participating Companies

## Company

## Category

**EndoCure**

Artificial Intelligence  
Population Health Management  
Remote Monitoring

**GrayMatters Health**

Artificial Intelligence

**Hopec Pharma**

Oncology  
Urology

**LuSeed Vascular**

Implantable  
Minimally Invasive System

**Nanocarry  
Therapeutics**

Drug delivery  
Minimally Invasive System

**New Phase**

Therapeutic Medical Device  
Minimally Invasive System

**NurExone Biologic**


Drug delivery  
Minimally Invasive System

**OrthoTreat**

Drug delivery  
Implantable  
Minimally Invasive System

**SurgiAI**

Artificial Intelligence  
Decision Support Systems  
Interoperability Enabling Tech



## AccuLine

[www.acculine-medical.com](http://www.acculine-medical.com)

### Therapeutic Areas

Cardiovascular

Primary Care

### Categories

Artificial

Intelligence

Decision Support  
Systems

Point of Care

Diagnostics

### Sub-Sector

Medical Device

### Funding Round

A

### Company Stage

Clinical Trials

**CORA is an AI-powered platform enabling CAD detection at primary care.**

AccuLine is developing CORA, a system to help PCPs detect CAD through a rapid, non-invasive test. CORA integrates sensor hardware with ML-based models to provide objective and accurate assessments at the point of care.

Unlike traditional exams that require referrals, imaging, and stress-based evaluations, CORA is designed to be accessible and easy to use. AccuLine is backed by strong investors such as eHealthventures, Macabbi Healthcare Services and Mayo Clinic.

**Video**





# ActualSignal Inc.

[www.actualsignal.com](http://www.actualsignal.com)

## Therapeutic Areas

Neurology and  
Degenerative Disease

Neuroscience

## Categories

Mobile Healthcare

Precision /  
Personalized Medicine

Remote Monitoring

## Sub-Sector

Digital Health

## Funding Round

Pre-Seed

## Company Stage

Commercial Product

## AI-powered smartphone app transforming Parkinson's care through early detection and proactive intervention

ActualSignal is an AI-powered care management platform for neurological conditions, starting with Parkinson's disease. Unlike wearables or clinic-based tools, our smartphone app transforms daily finger-tapping tests and passive gait monitoring into actionable clinical insights—achieving exceptional engagement among seniors.

We detect patient deterioration 2-3 weeks earlier than traditional care, reducing ER visits by 20-30%. Fully compatible with CCM and RTM billing codes, we generate revenue while lowering total care costs for ACOs and health plans.

Video



# AION LABS

The future of pharma

## AION Labs

[www.aionlabs.com](http://www.aionlabs.com)

### Therapeutic Areas

Autoimmune Diseases

Cardiovascular

Oncology

### Categories

Drug Discovery

Drug Development

### Sub-Sector

Digital Health

### Funding Round

A

### Company Stage

Proof of Concept

### Venture studio backed by leading pharma companies for AI/Pharma

AION Labs, is a first-of-its-kind venture studio of AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amity Ventures and Amazon Web Services (AWS) that have come together in the vibrant Israeli innovation ecosystem to create and adopt groundbreaking new AI technologies by building startups that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.



# Alma Therapeutics

[www.almatherapeutics.com](http://www.almatherapeutics.com)

## Therapeutic Areas

Autoimmune  
Diseases

Endocrinology

Obesity

## Categories

Drug Delivery

## Sub-Sector

Medical Device

## Funding Round

A

## Company Stage

Pre-clinical Stage

replacing injections with an oral drug-device capsule to deliver blockbuster biologic medications

Alma is developing a disruptive drug delivery system, replacing injections with a drug-device capsule capable of delivering biological drugs through the intestinal wall. After early preclinical success we initiated an agreement with a global pharma company to develop and oral version of a multi-billion-dollar injectable medication.

Video





# Appscents Medical

[www.appscents.com](http://www.appscents.com)

## Therapeutic Areas

Neurology and  
Degenerative Disease

General Health

Respiratory

## Categories

Assistive Technologies

Proactive wellness /  
Patient Engagement

Remote Monitoring

## Sub-Sector

Medical Device

## Funding Round

A+

## Company Stage

Commercial Product


## Olfactory Biofeedback Platform for Non-Invasive Sleep Therapy

Appscents Medical is disrupting sleep medicine with SCENTIFIC, the premier mask-free, FDA-registered Class II Olfactory Biofeedback Platform.

Unlike invasive CPAP or non-reimbursable consumer devices, our clinically validated technology drives high patient adherence and is fully integrated into the Remote Therapeutic Monitoring (RTM) reimbursement model, guaranteeing a scalable, recurring revenue pathway across home and institutional care.

Video





# Canopy Immuno-Therapeutics

[www.canopy-biotech.com](http://www.canopy-biotech.com)

## Therapeutic Areas

Autoimmune  
Diseases

## Categories

Precision /  
Personalized  
Medicine

## Sub-Sector

Bio Pharma

## Funding Round

A+

## Company Stage

Clinical Trials

## Antigen Drug Conjugates for the treatment of Autoimmune diseases

Canopy is pioneering a next-generation approach to treating autoimmune diseases by developing non-immunosuppressive, potentially curative biologics. The company's developed a unique platform of Antigen-Drug Conjugates (AgDCs), which precisely targets disease-causing antibodies and pathological B-cell clones while sparing 99.9% of protective immunity, a significant advancement over conventional treatments that rely on broad immunosuppression and often result in serious side effects.



## CoPilotMD

[www.linkedin.com/company/copilotmd](https://www.linkedin.com/company/copilotmd)

### Therapeutic Areas

Cardiovascular

Neurology and  
Degenerative Disease

Pulmonary

### Categories

Artificial Intelligence

Decision Support  
Systems

Hospital Operational  
Efficiency

### Sub-Sector

Digital Health

### Funding Round

Seed

### Company Stage

Proof of Concept

### Enabling clinicians with real-time solutions to avoid intra-operative complications

CoPilotMD is a pre-seed startup developing an intra-operative decision support platform revolutionizing minimally invasive surgeries. The platform, powered by AI, will integrate into a hospitals' interventional clinicians workflow and offer real time decision-support insights to serve as the physicians' 2nd set of eyes during surgical procedures.

The goal of the solution is to reduce complications and related costs, while boosting operational efficiency.



# Emet Surgical

[www.EmetSurgical.com](http://www.EmetSurgical.com)

## Therapeutic Areas

General Surgery

Gynecology

Infertility

## Categories

Artificial Intelligence

Decision Support  
Systems

Minimally Invasive  
System

## Sub-Sector

Medical Device

## Funding Round

Seed

## Company Stage

Clinical Trials

## Real-time AI Co-Pilot for MIS that monitors, alerts and provides decision support

ESP is a software-only surgical AI co-pilot that requires no specialized equipment, fluorescing agent infusions, or surgeon training. ESP's real-time decision support approach integrates seamlessly with existing laparoscopes and surgical robots, detecting anomalies and hidden lesions with amazing accuracy and speed.

ESP's platform approach addresses multiple applications: incidental cancer detection today, deep endometriosis lesions tomorrow, expanding surgical precision across specialties. ESP delivers immediate value to surgeons and their patients.

Video





## EndoCure

[www.endocure.tech](http://www.endocure.tech)

### Therapeutic Areas

Oncology

Urology

Women's Health

### Categories

Artificial  
Intelligence

Population Health  
Management

Remote Monitoring

### Sub-Sector

Medical Device

### Funding Round

Seed

### Company Stage

Clinical Trials

**Revealan transforms any ultrasound into a high-res, operator agnostic AI-powered imaging tool.**

Revealan™, our robotic ultrasound imaging platform, seamlessly integrates with any off-the-shelf ultrasound device to enable operator-agnostic, automated, AI-enabled, high-resolution 3D imaging. The robotic scan output is a series of standardized medical images with a density 10 times higher than that of an MRI

With Revealan™, we allow early detection and reliable follow-ups of small findings. Revealan™ is optimizing ultrasound for better patient outcomes.

Video





GrayMatters  
Health

# GrayMatters Health

[www.graymatters-health.com](http://www.graymatters-health.com)

## Therapeutic Areas

Psychiatry

## Categories

Precision / Personalized  
Medicine

## Sub-Sector

Digital Health

## Funding Round

B

## Company Stage

Commercial Product

**Prism is an interventional psychiatry suite powered by fMRI-Informed digital biomarkers for personalized patient care.**

GrayMatters Health is the first company to develop digital brain region specific biomarkers for mental health care. These proprietary biomarkers were developed by harnessing machine learning models to register fMRI data from deep in the brain to readily accessible EEG. This innovation enables patients to learn to regulate brain activity associated with their mental health condition in the clinic, gaining a skill for use in their daily lives.

Video





Bringing Hope to Bladder Cancer

## Hopec Pharma LTD

[hopec-pharma.com](http://hopec-pharma.com)

### Therapeutic Areas

General Health

Geriatrics

### Categories

Oncology

Urology

### Sub-Sector

Bio Pharma

### Funding Round

Seed

### Company Stage

Clinical Trials

### A Novel bacterial-based intravesical immunotherapy for bladder cancer

Hopec Pharma is developing UPEC-FimON, a differentiated intravesical immunotherapy for high-grade NMIBC that addresses the major limitations of BCG and current alternatives. Leveraging a unique FimH-driven immune activation, UPEC-FimON is designed to deliver stronger, more consistent anti-tumor responses for patients with few effective options.

Hopec has already initiated its first-in-human 60-patient Phase 1a/1b clinical trial at Hadassah and Sheba, supported by GMP batch and scalable manufacturing.



## LuSeed Vascular

[luseed-vascular.com](http://luseed-vascular.com)

### Therapeutic Areas

Cardiovascular

Peripheral Vascular

### Categories

Implantable

Minimally

Invasive System

### Company Stage

Clinical Trials

**The best-in-class, second generation solution for treating brain aneurysms**

LuSeed Vascular has developed a novel, minimal invasive solution to treat brain aneurysms, with clinical outcomes in over 20 patients presenting the best-in-class results in procedural time, ease of use and treatment effectiveness - Over 90% healing comparing with 50% standard of care - making it a true second-generation device.

The company is operating in a \$2.5 billion global market whose dynamics include 9 digit pre-FDA approval M&A transactions.

**Video**





# Nanocarry Therapeutics

[www.nanocarry.com](http://www.nanocarry.com)

## Therapeutic Areas

Neuroscience

Neurology and  
Degenerative  
Disease

Oncology

## Categories

Drug Delivery

Minimally Invasive  
System

## Sub-Sector

Bio Pharma

## Funding Round

A

## Company Stage

Proof of Concept

## Insulin-mediated nanocarrier platform enabling biologic therapeutics to reach the brain

Nanocarry Therapeutics is pioneering AxS, the first insulin-mediated nanocarrier platform capable of safely, traceably, and efficiently delivering biologic drugs across the blood-brain barrier (BBB). Its lead program, AxS007, targets HER2-positive breast cancer brain metastases.

Combining proven safety, exceptional brain penetration, and versatile payload compatibility, Nanocarry enables CNS delivery of therapeutics—unlocking new treatment possibilities and reviving drugs once limited by BBB exclusion.



## New Phase

[www.newphase.net](http://www.newphase.net)

### Therapeutic Areas

Oncology

### Categories

Therapeutic Medical Device

Minimally Invasive System

### Sub-Sector

Medical Device

### Funding Round

A

### Company Stage

Clinical Trials

### Novel Nanotechnology solution to prolong life of metastatic cancer patients

For people facing stage IV cancer, treatments can be limited, with low response rate, and severe side effects. Our approach focuses on prolonging patients' lives while preserving the quality that makes life meaningful by leveraging nanotechnology and electromagnetic systems.

The technology combines nanoparticles which are delivered to cancer tissues and are heated to 50°C using an Electromagnetic Induction System, causing destruction to the cancer cells, leaving healthy cells unharmed.

Video



# NurExone Biologic

[www.nurexone.com](http://www.nurexone.com)

## Therapeutic Areas

Dermatology and  
Aesthetics

Neurology and  
Degenerative Disease

Ophthalmology

## Categories

Drug Delivery

Minimally Invasive  
System

## Sub-Sector

Biotech

## Funding Round

Publicly Traded  
Company

(OTCQB:NRXBF) (TSXV:  
NRX) (FSE: J90)

## Company Stage

preclinical (IND  
enabling studies)

## ExoPTEN: Advancing minimally-invasive exosome therapy for spinal cord injury recovery

Nurexone is pioneering ExoPTEN, a groundbreaking minimally invasive exosome-based therapy for spinal cord injury (SCI) recovery. Unlike current treatments, ExoPTEN delivers targeted neural repair via non-surgical, accessible administration.

Our cutting-edge platform uniquely harnesses exosomes to cross the blood-brain barrier, aiming to restore function and improve quality of life for SCI patients, setting a new standard in neuroregenerative medicine with enhanced efficacy and patient accessibility.

Video





**OrthoTreat**

[www.orthotreat.io](http://www.orthotreat.io)

## Therapeutic Areas

Bone Diseases

Orthopedic

Women's Health

## Categories

Drug Delivery

Implantable

Minimally Invasive  
System

## Sub-Sector

Medical Device

## Funding Round

A

## Company Stage

Pre-Clinical

**First biologically orchestrated therapy platform delivering superior, safer bone regeneration.**

A preclinical biotech company developing ModulX® - the first dual-drug therapy platform that biologically orchestrates the full bone healing process rather than pushing a single pathway. While current grafts, biologics, and stimulators force tradeoffs between safety, efficacy, and cost, ModulX® delivers engineered synergy, controlled release, and a de-risked drug profile.

This enables faster, stronger, higher-quality healing with a superior safety margin and clear scalability across trauma, spine, osteoporosis and more.

**Video**





# SurgiAI

Guiding Every Surgical Step

## SurgiAI

[www.surgi.ai](http://www.surgi.ai)

### Therapeutic Areas

Neuroscience

### Categories

Artificial  
Intelligence

Decision Support  
Systems

Interoperability  
Enabling Tech

### Sub-Sector

Digital Health

### Funding Round

Seed

### Company Stage

Proof of Concept

**SurgiAI delivers real-time, adaptive AI surgical guidance for safer, more precise neurosurgery**

SurgiAI introduces the first neurosurgical guidance platform capable of continuously tracking soft-tissue anatomy, solving the accuracy loss that limits today's static navigation systems. Our real-time fusion of preoperative and intraoperative data delivers precision no competitor can match.

This unique capability not only improves outcomes and reduces costs—it positions SurgiAI at the forefront of a high-growth, multi-billion-dollar market seeking AI-powered, soft-tissue-adaptive surgical solutions

Video

